Antimicrobial Agents Practice Questions

Q: Which of the following antibacterial agents causes both ototoxicity and nephrotoxicity?

Vancomycin. **Explanation:** **Vancomycin** is a glycopeptide antibiotic primarily used for MRSA and other resistant Gram-positive infections [1]. Its side effect profile is a high-yield topic for NEET-PG. While modern, highly purified formulations have reduced the incidence, Vancomycin is classically associated with **nephrotoxicity** (acute kidney injury) and **ototoxicity** (tinnitus or hearing loss) [2]. These risks are significantly increased when Vancomycin is administered concurrently with other ototoxic/nephrotoxic drugs, such as Aminoglycosides or Loop diuretics [3]. **Analysis of Incorrect Options:** * **Clindamycin (A):** A lincosamide known for causing gastrointestinal distress and is the classic culprit for **Pseudomembranous colitis** (caused by *C. difficile* overgrowth). It does not cause ear or kidney damage. * **Azithromycin (B):** A macrolide antibiotic. While it can rarely cause transient hearing loss at very high doses, it is not nephrotoxic. Its primary side effects are GI upset and QT interval prolongation. * **Methicillin (C):** An older penicillin (now replaced by Oxacillin/Nafcillin). It is famously associated with **interstitial nephritis** (hypersensitivity reaction), but it is not ototoxic. **Clinical Pearls for NEET-PG:** * **Red Man Syndrome:** A common infusion-related reaction of Vancomycin caused by direct histamine release (not a true allergy). It is prevented by slowing the infusion rate. * **Therapeutic Drug Monitoring (TDM):** Essential for Vancomycin to maintain trough levels (typically 15–20 µg/mL) to minimize toxicity [3]. * **Mnemonic for Vancomycin Toxicity:** **"NOT"** – **N**ephrotoxicity, **O**totoxicity, **T**hrombophlebitis (and Red Man Syndrome).

Q: Which of the following protease inhibitors has an active metabolite?

Nelfinavir. **Explanation:** **Nelfinavir** is unique among the HIV protease inhibitors (PIs) because it is metabolized primarily by the CYP2C19 isoenzyme into an **active metabolite** known as **M8 (hydroxy-t-butylamide)**. This metabolite possesses antiviral potency nearly equal to that of the parent drug, contributing significantly to its overall therapeutic efficacy. **Analysis of Options:** * **Nelfinavir (Correct):** It is the only PI listed that produces a major active metabolite. It is also notable for being one of the few PIs that does not strictly require "boosting" with ritonavir, though it is frequently associated with diarrhea as a side effect. * **Ritonavir:** While it is a potent inhibitor of CYP3A4 (used as a "pharmacokinetic booster"), its own metabolites are not clinically significant for antiviral activity. * **Indinavir:** Metabolized by the liver into inactive metabolites. It is clinically associated with nephrolithiasis (crystalluria) and requires high fluid intake. * **Saquinavir:** The first PI developed; it has low bioavailability and is metabolized into inactive compounds. **High-Yield NEET-PG Pearls:** * **Metabolic Side Effects:** All Protease Inhibitors are associated with **lipodystrophy** (buffalo hump), hyperlipidemia, and insulin resistance. * **Ritonavir Boosting:** Ritonavir is used at low doses to inhibit CYP3A4, thereby increasing the plasma concentration and half-life of other PIs (e.g., Lopinavir). * **Atazanavir:** Known for causing unconjugated hyperbilirubinemia and requires an acidic gastric pH for absorption (avoid PPIs). * **Darunavir:** Currently a preferred PI; contains a sulfonamide moiety (caution in sulfa allergy).

Q: All of the following drugs can cause hearing loss except?

Metronidazole. **Explanation:** The correct answer is **Metronidazole**. Ototoxicity (hearing loss and tinnitus) is a well-documented side effect of several classes of drugs, but Metronidazole is primarily associated with **neurotoxicity** (peripheral neuropathy, ataxia, and seizures) rather than auditory damage. **Why the other options are incorrect:** * **Kanamycin (Aminoglycosides):** These are the most notorious causes of ototoxicity. They cause irreversible damage to the hair cells in the cochlea (hearing loss) and the vestibular apparatus (balance issues) by generating reactive oxygen species. * **Vancomycin (Glycopeptides):** While less common than aminoglycosides, vancomycin can cause ototoxicity, especially when administered in high doses, in patients with renal impairment, or when used synergistically with other ototoxic drugs. * **Quinine (Antimalarials):** Quinine and its isomer quinidine cause a specific syndrome called **Cinchonism**, characterized by tinnitus, high-frequency hearing loss, dizziness, and visual disturbances. This is usually reversible upon discontinuation. **High-Yield Clinical Pearls for NEET-PG:** 1. **Ototoxic Drug Classes:** * **Aminoglycosides:** Neomycin (most toxic), Amikacin, Kanamycin, Gentamicin. * **Loop Diuretics:** Furosemide, Ethacrynic acid (highest risk). * **Chemotherapy:** Cisplatin, Carboplatin. * **Salicylates:** High-dose Aspirin (causes reversible tinnitus). 2. **Metronidazole Key Fact:** It is the drug of choice for anaerobic infections and pseudomembranous colitis. Its unique side effect is a **Disulfiram-like reaction** when consumed with alcohol. 3. **Monitoring:** Patients on long-term aminoglycosides or vancomycin should undergo periodic **audiometry** and renal function tests.

Q: Which drug acts fastest on the Mycobacterium leprae bacilli?

Rifampicin. **Explanation:** **Rifampicin** is the correct answer because it is the most potent and fastest-acting bactericidal drug against *Mycobacterium leprae*. It acts by inhibiting the DNA-dependent RNA polymerase enzyme, thereby halting bacterial protein synthesis. A single dose of 600 mg is capable of killing **99.9% of viable bacilli** within 3 to 7 days. Due to this rapid action, patients typically become non-infectious within a week of starting treatment. **Analysis of Incorrect Options:** * **Dapsone (B):** While it is the backbone of leprosy treatment, it is primarily **bacteriostatic**. It works by inhibiting dihydropteroate synthase (folate synthesis). It acts slowly and requires long-term administration to clear the bacterial load. * **Kanamycin (C):** This is an aminoglycoside occasionally used in drug-resistant cases, but it is not a first-line agent and does not match the rapid bactericidal efficacy of Rifampicin in leprosy. * **Clofazimine (D):** This is a **bacteriostatic/weakly bactericidal** dye used in Multi-Drug Therapy (MDT). Its action is very slow, and it is primarily valued for its anti-inflammatory properties in managing Type 2 Lepra reactions (ENL). **High-Yield Clinical Pearls for NEET-PG:** * **MDT Regimen:** For Paucibacillary (PB) leprosy, treatment lasts 6 months; for Multibacillary (MB) leprosy, it lasts 12 months. * **Rifampicin Side Effect:** Can cause orange-discoloration of urine and secretions (harmless) and hepatotoxicity. * **Clofazimine Side Effect:** Causes brownish-black skin discoloration and ichthyosis. * **Dapsone Side Effect:** Hemolysis (especially in G6PD deficiency) and "Dapsone Syndrome" (exfoliative dermatitis, fever, and lymphadenopathy).

Q: Which of the following drugs is NOT used in the treatment of extended drug resistance?

Rifampicin. The question focuses on the definitions and treatment protocols for drug-resistant tuberculosis (TB), a high-yield topic for NEET-PG. ### **Explanation of the Correct Answer** **A. Rifampicin** is the correct answer because, by definition, **Extensively Drug-Resistant TB (XDR-TB)** is defined as TB that is resistant to at least **Isoniazid and Rifampicin** (MDR-TB), plus resistance to any fluoroquinolone and at least one of the three injectable second-line drugs (Amikacin, Kanamycin, or Capreomycin). Since Rifampicin resistance is a prerequisite for the diagnosis of XDR-TB, it is inherently ineffective and **not used** in its treatment. ### **Analysis of Incorrect Options** * **B. Isoniazid:** While XDR-TB is resistant to standard doses of Isoniazid, **High-dose Isoniazid** is sometimes included in WHO-recommended shorter regimens for drug-resistant TB if specific mutations (like *inhA* promoter mutations) suggest low-level resistance that can be overcome. * **C. Moxifloxacin:** This is a later-generation fluoroquinolone. While XDR-TB is resistant to "a" fluoroquinolone, newer agents like **high-dose Moxifloxacin** or Gatifloxacin were historically part of salvage regimens, though BPaL (Bedaquiline, Pretomanid, Linezolid) is now preferred. * **D. Capreomycin:** This is a cyclic peptide (injectable second-line drug). It was a mainstay in the treatment of MDR-TB and used in XDR-TB cases where sensitivity was still preserved to at least one injectable agent. ### **NEET-PG High-Yield Pearls** * **MDR-TB:** Resistance to Isoniazid (H) + Rifampicin (R). * **Pre-XDR-TB:** MDR-TB + resistance to any Fluoroquinolone. * **XDR-TB (New WHO Definition):** MDR-TB + resistance to any Fluoroquinolone + resistance to at least one Group A drug (**Bedaquiline or Linezolid**). * **Drug of Choice for XDR-TB:** The **BPaL regimen** (Bedaquiline, Pretomanid, and Linezolid) is currently the standard of care.

Q: In antiretroviral therapy, which of the following drugs should not be combined with Zidovudine?

Stavudine. ### Explanation The correct answer is **Stavudine (D)**. **Why Stavudine is the correct answer:** Both **Zidovudine (AZT)** and **Stavudine (d4T)** are Nucleoside Reverse Transcriptase Inhibitors (NRTIs) that act as **thymidine analogs**. To become active, they must be phosphorylated by the same intracellular enzyme, **thymidine kinase**. When administered together, they compete for this enzyme. Zidovudine has a higher affinity for thymidine kinase and effectively inhibits the phosphorylation (activation) of Stavudine. This results in a **pharmacodynamic antagonism**, rendering the combination clinically ineffective and increasing the risk of toxicity without therapeutic benefit. **Analysis of Incorrect Options:** * **A. Lamivudine (3TC):** This is a cytosine analog. It uses different phosphorylation pathways and is the most common partner for Zidovudine (e.g., the Combivir regimen) due to synergistic effects. * **B. Nevirapine:** This is a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). It has a completely different mechanism of action (binding directly to the enzyme) and is frequently combined with Zidovudine in NNRTI-based regimens. * **C. Didanosine (ddI):** This is a purine (adenosine) analog. It does not compete with Zidovudine for activation and was historically used in dual NRTI combinations. **High-Yield Clinical Pearls for NEET-PG:** * **Zidovudine (AZT) Side Effects:** Macrocytic anemia (most common) and bone marrow suppression. It is the drug of choice for preventing mother-to-child transmission (MTCT) during labor. * **Stavudine (d4T) Side Effects:** Highest risk of peripheral neuropathy and lipodystrophy among NRTIs. * **Mnemonic:** Remember **"Z"** and **"S"** (Zidovudine and Stavudine) are both **Thymidine** analogs—they "Stay" away from each other to avoid competition.

Q: All of the following are useful in the management of severe Clostridium difficile infection, except?

Neomycin enema. **Explanation:** The management of *Clostridioides difficile* infection (CDI) focuses on agents that reach therapeutic concentrations in the colon and possess activity against anaerobic gram-positive bacilli. **Why Neomycin is the correct answer (Except):** Neomycin is an aminoglycoside. Aminoglycosides are strictly aerobic in their mechanism of action (requiring oxygen for uptake into the bacterial cell) and are **ineffective against anaerobes** like *C. difficile*. Furthermore, neomycin is highly nephrotoxic and ototoxic if absorbed, and its use is generally limited to bowel preparation or hepatic encephalopathy. It has no role in treating CDI. **Analysis of other options:** * **Oral Vancomycin:** This is the **first-line treatment** for severe CDI. It is not absorbed systemically, ensuring high intraluminal concentrations directly at the site of infection. * **IV Metronidazole:** While oral metronidazole is used for mild cases, IV metronidazole is added to oral vancomycin in **fulminant/complicated** cases (e.g., ileus or shock) because it reaches the inflamed colon via biliary secretion and systemic circulation. * **Tigecycline:** This is a glycylcycline with broad-spectrum activity, including potent anti-anaerobic properties. It is considered a **rescue therapy** for refractory or severe CDI when standard treatments fail. **NEET-PG High-Yield Pearls:** 1. **Drug of Choice:** Oral Vancomycin or Fidaxomicin (Fidaxomicin has lower recurrence rates). 2. **Metronidazole:** Only antibiotic used **IV** for CDI (Vancomycin must be oral/rectal). 3. **Bezlotoxumab:** A monoclonal antibody against Toxin B used to prevent recurrence. 4. **Fecal Microbiota Transplant (FMT):** Indicated for multiple recurrences of CDI.

Q: What is the drug of choice for non-gonococcal urethritis?

Doxycycline. **Explanation:** **Non-gonococcal urethritis (NGU)** is most commonly caused by *Chlamydia trachomatis*, followed by *Mycoplasma genitalium*. 1. **Why Doxycycline is correct:** According to the latest CDC and WHO guidelines, **Doxycycline (100 mg twice daily for 7 days)** is the first-line drug of choice for NGU. It is a bacteriostatic tetracycline that inhibits protein synthesis by binding to the 30S ribosomal subunit. It is highly effective against intracellular organisms like *Chlamydia*. While Azithromycin (1g single dose) was previously preferred for compliance, Doxycycline is now favored due to superior efficacy against *Mycoplasma genitalium* and rectal chlamydial infections. 2. **Why the other options are incorrect:** * **Tetracycline:** While in the same class, it requires four-times-daily dosing and has more gastrointestinal side effects and lower bioavailability compared to Doxycycline. * **Ciprofloxacin:** This is a fluoroquinolone. While it has some activity against Gram-negative bacteria, it is not the primary choice for NGU due to rising resistance and inferior efficacy against *Chlamydia* compared to tetracyclines. * **Ceftriaxone:** This is a third-generation cephalosporin and the **drug of choice for Gonococcal urethritis** (Gonorrhea). It is ineffective against *Chlamydia* because *Chlamydia* lacks a traditional peptidoglycan cell wall. **High-Yield Clinical Pearls for NEET-PG:** * **Syndromic Management (Kit 1):** In India, under the NACO guidelines, the Grey Kit (Azithromycin 1g + Cefixime 400mg) is used for the syndromic management of urethral discharge to cover both Gonorrhea and NGU. * **Pregnancy:** Doxycycline is contraindicated in pregnancy (teratogenic - causes bone/teeth discoloration). In pregnant patients with NGU, **Azithromycin** is the drug of choice. * **Co-infection:** Always treat for both Gonorrhea and Chlamydia if the specific pathogen is not identified.

Question 1

Streptomycin single dose is more effective than multiple small doses because it is -

Accepted Answer

Concentration dependent lytic effect

Answer

Longer half-life

Answer

Not dependent on renal clearance

Answer

Tubular secretion and reabsorption is more

Question 2

Which of the following antibacterial agents causes both ototoxicity and nephrotoxicity?

Accepted Answer

Vancomycin

Answer

Clindamycin

Answer

Azithromycin

Answer

Methicillin

Question 3

Which of the following protease inhibitors has an active metabolite?

Accepted Answer

Nelfinavir

Answer

Ritonavir

Answer

Indinavir

Answer

Saquinavir

Question 4

All of the following drugs can cause hearing loss except?

Accepted Answer

Metronidazole

Answer

Vancomycin

Answer

Kanamycin

Answer

Quinine

Question 5

All of the following are true about Praziquantel except?

Accepted Answer

It increases the permeability for calcium ions and leads to flaccid paralysis of helminths.

Answer

It is the drug of choice for intestinal Taenia solium infection.

Answer

It is the drug of choice for schistosomiasis.

Answer

Side effects include myalgia and arthralgia.

Question 6

Which drug acts fastest on the Mycobacterium leprae bacilli?

Accepted Answer

Rifampicin

Answer

Dapsone

Answer

Kanamycin

Answer

Clofazimine

Question 7

Which of the following drugs is NOT used in the treatment of extended drug resistance?

Accepted Answer

Rifampicin

Answer

Isoniazid

Answer

Moxifloxacin

Answer

Capreomycin

Question 8

In antiretroviral therapy, which of the following drugs should not be combined with Zidovudine?

Accepted Answer

Stavudine

Answer

Lamivudine

Answer

Nevirapine

Answer

Didanosine

Question 9

All of the following are useful in the management of severe Clostridium difficile infection, except?

Accepted Answer

Neomycin enema

Answer

Oral vancomycin

Answer

IV metronidazole

Answer

Tigecycline

Question 10

What is the drug of choice for non-gonococcal urethritis?

Accepted Answer

Doxycycline

Answer

Tetracycline

Answer

Ciprofloxacin

Answer

Ceftriaxone

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?